605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I

Co-Targeting BCL-2 and MCL1 (via CDK9) in Pre-Clinical Models of High-Risk Acute Lymphoblastic Leukemia

Cytarabine Resistance Leads to a Specific Mutator Phenotype in Leukemic Cells

Development of an Antibody-Drug Conjugate Targeting CADM1 in Adult T-Cell Leukemia/Lymphoma

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)

Exposure-Response Analyses Supporting Optimal Epcoritamab Full Dose and Dosing Schedule in Relapsed or Refractory Follicular Lymphoma

Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma

Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL

JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling

TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL

Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

The Polymeric Drug Pamd-Ch17 Induces Mitochondrial Dysfunction and Has Anti-Leukemic Effects